Skip to main content

Sutro Biopharma, Inc. (STRO) Stock Forecast

Data as of Aug 5, 2026

Healthcare · Current price $25.80 (+2.79%)

Consensus Target
$50.75
Upside
+112.5%
Analysts
8
Rating
Buy(2.00)

Price Target Range

Low $43.00Consensus $50.75High $60.00
▲ Current $25.80

Consensus Price Target Over Time

Analyst Rating Distribution

Last 3 Months

Consensus
Buy
Strong Buy0
Buy3
Hold0
Sell0
Strong Sell0

6-Month Trend

Latest Analyst Forecasts

Price targets issued by Wall Street analysts. Upside calculated against today's price.

No analyst price targets available.

STRO vs Sector & Market

MetricSTROHealthcare AvgLarge Cap Avg
Analyst Rating2.002.252.42
Analyst Count8818
Target Upside+112.5%+16316.0%+17.1%
P/E Ratio-1.563.3336.31

Revenue Estimates

PeriodLowAvgHigh#
2026-09-30$6M$8M$11M4
2026-12-31$6M$8M$11M4
2027-03-31$1M$2M$3M4
2027-06-30$12M$17M$22M3
2027-09-30$13M$18M$24M3
2027-12-31$13M$19M$25M3
2028-12-31$11M$38M$67M7
2029-12-31$15M$55M$97M3
2030-12-31$20M$71M$125M6

EPS Estimates

PeriodLowAvgHigh#
2026-09-30$-3.72$-2.66$-1.603
2026-12-31$-3.55$-2.54$-1.523
2027-03-31$-3.21$-2.30$-1.383
2027-06-30$-3.11$-2.23$-1.342
2027-09-30$-3.08$-2.20$-1.322
2027-12-31$-2.76$-1.97$-1.182
2028-12-31$-14.11$-7.93$-1.736
2029-12-31$-14.75$-7.44$-0.454
2030-12-31$-12.14$-6.12$-0.372

Frequently Asked Questions

What is the analyst consensus for STRO?

The consensus among 8 analysts covering Sutro Biopharma, Inc. (STRO) is Buy with an average price target of $50.75.

What is the highest price target for STRO?

The highest analyst price target for STRO is $60.00.

What is the lowest price target for STRO?

The lowest analyst price target for STRO is $43.00.

How many analysts cover STRO?

8 analysts have issued ratings for Sutro Biopharma, Inc. in the past 12 months.

Is STRO a buy or sell right now?

Based on 8 analyst ratings, STRO has a consensus rating of Buy (2.00/5) with a +112.5% upside to the consensus target of $50.75.

What are the earnings estimates for STRO?

Analysts estimate STRO will report EPS of $-2.66 for the period ending 2026-09-30, with revenue estimated at $8M.

Data updated daily. Analyst price targets sourced from public filings and broker reports. Not investment advice.